Scientists Develop New Antibody to Target HIV Strains

In 2016, HIV continued to confound patients, physicians, and researchers while resulting in one million deaths due to AIDS-related illness worldwide. Additionally, there were 36.7 million people living with HIV and 1.8 million new HIV infections reported. HIV mutational ability generally inactivates the immune system leading to lethal virulence.

As a result of a collaboration between Sanofi and the United States National Institutes of Health, research scientists have developed a revolutionary tri-specific antibody designed to target three separate components of HIV, disrupting resistance mechanisms that render accepted therapeutic paradigms ineffective.

Preliminary studies reveal that in twenty-four monkeys treated with the antibody and then infected with HIV, no test subjects progressed to developing symptoms or advanced disease. Beginning in 2018, the tri-specific antibody will be tested in humans.

HIV life expectancy is improving. A new study published in The Lancet reports advances in antiretroviral drug treatment (ART) that improve life expectancy for patients living with HIV. ART is the standard treatment regime for HIV patients. While ART cannot cure HIV, a combination of medications help patients live longer and reduce the risk of HIV transmission. ART was first introduced in 1996. One year after ART was introduced, the FDA approved Combivir, a combination drug taken as a single daily tablet, which made taking daily medication HIV patients easier. Since then, ART initiation has improved by leaps and bounds, making medication management easier for patients.


Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Do Kwon Y, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O’Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017 Sep 20. pii: eaan8630. doi: 10.1126/science.aan8630. [Epub ahead of print] PubMed PMID: 28931639.

2859 Total Views 7 Views Today

The Doctor's Channel

Take a bite from the adults' table. The Doctor’s Channel is the world’s leading video site for physicians. Get the latest news in clinical medicine, disease resource centers, CME programs, and Doc Life, all in under 3 mins or less.